SLC35E2A: A Potential Drug Target and Biomarker (G9906)

Target Name: SLC35E2A

NCBI ID: G9906

SLC35E2A

SLC35E2A: A Potential Drug Target and Biomarker

Sodium-glucose cotransporter 35 (SLC35E2A) is a member of thesolute carrier family 35, which is a well-established family of transmembrane proteins that play a crucial role in the transport of a variety of molecules across cell membranes. SLC35E2A is a 31-kDa protein that is expressed in most tissues and cells, including the brain, heart, and kidney. Its function in cell signaling and drug transport has been extensively studied, and it is considered a potential drug target and biomarker.

SLC35E2A is a transmembrane protein that is involved in the transport of both Na+ and GLUT4, a protein that is involved in glucose uptake and storage in the body. SLC35E2A is composed of an N-terminus, a catalytic region, and a C-terminus that is involved in the interaction with other proteins. The catalytic region of SLC35E2A contains two distinct domains: an N-terminal alpha-helices domain and a C-terminal alpha-helical domain. The N-terminal domain is responsible for the protein's catalytic activity, while the C-terminal domain is involved in the protein's stability and interaction with other proteins.

SLC35E2A is a key protein that is involved in the regulation of a variety of physiological processes in the body. For example, SLC35E2A is involved in the regulation of ion and water transport in the brain, as well as the regulation of blood pressure. It is also involved in the regulation of cell signaling, as many signaling pathways that are critical for cellular function require the transport of specific molecules across cell membranes. SLC35E2A is a key component of several signaling pathways that are critical for brain development, neurotransmission, and survival.

SLC35E2A is also a potential drug target, as several studies have identified its involvement in several diseases and drug-induced neurodegeneration. For example, SLC35E2A has been shown to be involved in the regulation of the blood-brain barrier, which is responsible for protecting the brain from harmful substances that are produced by other parts of the body. In addition, SLC35E2A has been shown to be involved in the regulation of neurotransmitter release from neurons, which is critical for the brain's complex signaling processes.

SLC35E2A is also a potential biomarker for several diseases, including Alzheimer's disease, Parkinson's disease, and neurodegenerative disorders. The loss of SLC35E2A has been observed in the brains of individuals with these disorders, and its levels are often decreased in the brains of individuals with these disorders. disorders compared to age-matched controls. These findings suggest that SLC35E2A may be a useful biomarker for the diagnosis and treatment of these disorders.

In conclusion, SLC35E2A is a well-established member of thesolute carrier family 35 that is involved in the regulation of a variety of physiological processes in the body. Its function in cell signaling and drug transport has been extensively studied, and it is considered a potential drug target and biomarker. Further research is needed to fully understand the role of SLC35E2A in disease and to develop effective treatments.

Protein Name: Solute Carrier Family 35 Member E2A

Functions: Putative transporter

The "SLC35E2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35E2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets